GKOS

152.72

1.52% -2.35

Dopo l'orario di chiusura: 152.72

Glaukos Corp (GKOS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$155.07

Aprire:

$154.05

Volume 24 ore:

672.33K

Relative Volume:

0.69

Capitalizzazione di mercato:

$8.97B

Reddito:

$551.35M

Utile/perdita netta:

$-189.33M

Rapporto P/E:

-46.40

EPS:

-3.2916

Flusso di cassa netto:

$-35.09M

1 W Prestazione:

+2.95%

1M Prestazione:

+24.68%

6M Prestazione:

+35.25%

1 anno Prestazione:

+43.33%

Intervallo 1D:

$143.11

$156.60

Intervallo di 1 settimana:

$143.11

$156.60

Portata 52W:

$73.16

$156.60

Glaukos Corp Stock (GKOS) Company Profile

Nome

Glaukos Corp

Settore

Healthcare (1096)

Industria

Medical Devices (140)

Telefono

949-367-9600

Indirizzo

1 GLAUKOS WAY, ALISO VIEJO, CA

Dipendente

1,094

Cinguettio

@GlaukosCorp

Prossima data di guadagno

2026-07-29

Ultimi documenti SEC

GKOS's Discussions on Twitter

Compare GKOS vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GKOS Glaukos Corp	152.72	9.11B	551.35M	-189.33M	-35.09M	-3.2916
ABT Abbott Laboratories	93.93	164.43B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	329.78	125.40B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.87	105.46B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	44.77	66.87B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	92.21	52.59B	6.30B	1.07B	1.09B	1.8406

Glaukos Corp Stock (GKOS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-27	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2025-10-01	Iniziato	Goldman	Buy
2025-05-01	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-02-19	Aggiornamento	Mizuho	Neutral → Outperform
2024-12-11	Aggiornamento	Citigroup	Neutral → Buy
2024-12-06	Iniziato	UBS	Buy
2024-12-02	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2024-07-10	Downgrade	Citigroup	Buy → Neutral
2024-05-06	Aggiornamento	Jefferies	Hold → Buy
2023-12-21	Aggiornamento	JP Morgan	Neutral → Overweight
2023-12-04	Iniziato	Morgan Stanley	Equal-Weight
2023-11-28	Iniziato	Truist	Buy
2023-11-08	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-06-07	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-12-22	Iniziato	Mizuho	Neutral
2022-12-19	Aggiornamento	JP Morgan	Underweight → Neutral
2022-12-12	Aggiornamento	Citigroup	Neutral → Buy
2022-10-14	Ripresa	Stephens	Overweight
2022-10-04	Iniziato	Needham	Buy
2022-07-12	Aggiornamento	Stifel	Hold → Buy
2022-02-03	Aggiornamento	William Blair	Mkt Perform → Outperform
2022-01-19	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2022-01-18	Aggiornamento	BTIG Research	Neutral → Buy
2021-11-03	Aggiornamento	Stephens	Equal-Weight → Overweight
2021-07-26	Downgrade	Stephens	Overweight → Equal-Weight
2021-07-20	Downgrade	Wells Fargo	Equal Weight → Underweight
2021-07-14	Downgrade	Oppenheimer	Outperform → Perform
2021-07-14	Downgrade	William Blair	Outperform → Mkt Perform
2021-04-08	Aggiornamento	Oppenheimer	Perform → Outperform
2021-01-29	Downgrade	Piper Sandler	Overweight → Neutral
2020-12-16	Aggiornamento	Citigroup	Sell → Neutral
2020-12-09	Iniziato	Oppenheimer	Perform
2020-11-17	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2020-10-08	Downgrade	JP Morgan	Neutral → Underweight
2020-06-15	Iniziato	Jefferies	Hold
2020-03-05	Iniziato	Citigroup	Sell
2020-02-28	Downgrade	JP Morgan	Overweight → Neutral
2020-01-06	Aggiornamento	Berenberg	Hold → Buy
2019-12-12	Downgrade	Wells Fargo	Outperform → Underperform
2019-09-30	Downgrade	BofA/Merrill	Buy → Underperform
2019-03-08	Iniziato	BTIG Research	Neutral
2018-08-30	Iniziato	Berenberg	Hold
2018-08-29	Aggiornamento	JP Morgan	Neutral → Overweight
2018-08-03	Reiterato	Stifel	Hold
2018-06-21	Downgrade	JP Morgan	Overweight → Neutral
2018-04-13	Downgrade	Stifel	Buy → Hold
2018-03-01	Reiterato	Cantor Fitzgerald	Buy
2017-03-02	Reiterato	Cantor Fitzgerald	Overweight
2017-01-06	Aggiornamento	Stifel	Hold → Buy
2016-10-27	Iniziato	Wells Fargo	Outperform

Mostra tutto

Glaukos Corp Borsa (GKOS) Ultime notizie

Jul 10, 2026

Midday Stock Roundup: Alignment Healthcare Up 7.8% Ahead of Q2 Results - Orange County Business Journal

Jul 09, 2026

Glaukos (GKOS) Form 144 shows 10,000-share sale, option exercise - Stock Titan

Jul 09, 2026

Jul 08, 2026

Glaukos Corp CFO Alex Thurman sells $1.5m in shares - Investing.com

Jul 08, 2026

Form 4 Glaukos Corp For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026

Glaukos chief development officer Navratil sells $99,566 stock By Investing.com - Investing.com Nigeria

Jul 08, 2026

Glaukos (GKOS) CFO executes pre-planned share sale and option exercise - Stock Titan

Jul 08, 2026

Glaukos chief development officer Navratil sells $99,566 stock - Investing.com

Jul 08, 2026

Glaukos (GKOS) chief development officer sells 716 shares under 10b5-1 plan - Stock Titan

Jul 08, 2026

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Jul 08, 2026

GKOS Maintained by Citigroup -- Price Target Raised to $175 - GuruFocus

Jul 08, 2026

GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally? - Yahoo Finance

Jul 08, 2026

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 - Business Wire

Jul 08, 2026

Jul 07, 2026

Glaukos Corp stock and its role in eye disease treatment - ad-hoc-news.de

Jul 07, 2026

Jul 06, 2026

Form 144 GLAUKOS Corp For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

Glaukos (NYSE: GKOS) files Form 144 to sell 10,000 shares - Stock Titan

Jul 06, 2026

Glaukos stock rating reiterated at Outperform by William Blair - Investing.com

Jul 06, 2026

Jul 02, 2026

Glaukos Rises as Reimbursement Milestone and Recent Pipeline Updates Support Sentiment - Quiver Quantitative

Jul 02, 2026

Glaukos stock hits 52-week high at 148.12 USD By Investing.com - Investing.com Nigeria

Jul 02, 2026

Glaukos stock hits 52-week high at 148.12 USD - Investing.com

Jul 02, 2026

Jul 01, 2026

Form 144 GLAUKOS Corp For: 1 July - Investing.com UK

Jul 01, 2026

Form 144 GLAUKOS Corp For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

GKOS (GKOS) insider sells 3,630 shares total across April and June 2026 - Stock Titan

Jul 01, 2026

GKOS Reiterated by Piper Sandler -- Price Target Maintained at $165 - GuruFocus

Jul 01, 2026

Piper Sandler reiterates Glaukos stock rating on iDose headwinds By Investing.com - Investing.com Nigeria

Jul 01, 2026

Piper Sandler reiterates Glaukos stock rating on iDose headwinds - Investing.com

Jul 01, 2026

Jun 29, 2026

Form 4 Glaukos Corp For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Glaukos (NYSE: GKOS) CEO updates trust holdings, uses shares for tax withholding - Stock Titan

Jun 29, 2026

Form 4 Glaukos Corp For: 29 June - Investing.com UK

Jun 29, 2026

Glaukos (NYSE: GKOS) president has 1,056 shares withheld for taxes - Stock Titan

Jun 29, 2026

Glaukos (GKOS) CDO reports 483-share tax withholding, holds 88,350 shares - Stock Titan

Jun 29, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Glaukos Corp – XETR:6GJ - TradingView

Jun 27, 2026

Jun 26, 2026

Price to book forward of Glaukos Corp – XETR:6GJ - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of Glaukos Corp – XETR:6GJ - TradingView

Jun 26, 2026

Jun 25, 2026

Goldman Sachs Small Cap Equity Insights Fund's Glaukos Corp(GKOS) Holding History - GuruFocus

Jun 25, 2026

Glaukos Corp Actuals & Estimates (NYSE:GKOS) - TradingView

Jun 25, 2026

Glaukos Moves Into Demodex Blepharitis Space - Orange County Business Journal

Jun 25, 2026

Glaukos completes enrollment in phase 2 blepharitis study - Investing.com

Jun 25, 2026

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis - BioSpace

Jun 25, 2026

Glaukos completes enrollment in phase 2 blepharitis study By Investing.com - Investing.com Australia

Jun 25, 2026

Glaukos (GKOS) Completes Patient Enrollment in GLK-321 Study - GuruFocus

Jun 25, 2026

Glaukos fills 275-patient trial of eyelid-disease drug candidate - Stock Titan

Jun 25, 2026